Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

PURPOSE: Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma. EXPERIMENTAL DESIGN: A panel of 116 small m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2015
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662464/
https://ncbi.nlm.nih.gov/pubmed/26254279
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak